Background. Oxidative stress in schizophrenia may be caused partially by the treatment of patients with antipsychotics. The aim of the study was to establish the effects of polyphenol compounds derived from berries of Aronia melanocarpa (Aronox) on the plasma lipid peroxidation induced by ziprasidone in vitro. Methods. Lipid peroxidation was measured by the level of thiobarbituric acid reactive species (TBARS). The samples of plasma from healthy subjects were incubated with ziprasidone (40？ng/ml; 139？ng/ml; and 250？ng/ml) alone and with Aronox (5？ug/ml; 50？ug/ml). Results. We observed a statistically significant increase of TBARS level after incubation of plasma with ziprasidone (40？ng/ml; 139？ng/ml; and 250？ng/ml) (after 24？h incubation: × 10？4, × 10？3, and × 10？3, resp.) and Aronox lipid peroxidation caused by ziprasidone was significantly reduced. After 24-hour incubation of plasma with ziprasidone (40？ng/ml; 139？ng/ml; and 250？ng/ml) in the presence of 50？ug/ml Aronox, the level of TBARS was significantly decreased: × 10？8, × 10？6, and × 10？5, respectively. Conclusion. Aronox causes a distinct reduction of lipid peroxidation induced by ziprasidone. 1. Introduction Oxidative stress plays an important role in schizophrenia and other psychiatric disorders. Schizophrenia is a chronic psychiatric disorder that affects at young age many cultures around the world. The aetiology of schizophrenia remains elusive, although several hypotheses have been suggested including abnormalities in cell membrane phospholipids metabolism or its alteration and dysfunction of cell membranes. Oxidative stress plays an important role in the pathophysiology of schizophrenia [1–9]. In schizophrenic patients, dysregulation of reactive oxygen species (ROS) generation and metabolism, as detected by abnormal activities of critical antioxidant enzymes and other indicators such as lipid peroxidation in plasma, red blood cells, blood platelets, and cerebrospinal fluid, are observed [3, 10–12]. It is well known that oxidative stress with peroxidation of polyunsaturated fatty acids (PUFA) in the membrane can lead to the abnormalities that have been observed in schizophrenia [11, 13, 14]. Oxidative stress occurs when the production of ROS exceeds the natural antioxidant defence mechanisms, causing damage to macromolecules such as DNA, proteins, and lipids. Antioxidant defence mechanisms remove the free radicals to prevent oxidative damage to biomolecules. The antioxidant system comprises of different types of functional components such as enzymatic (superoxide dismutase, catalase,
References
[1]
H.-G. Bernstein, B. Bogerts, and G. Keilhoff, “The many faces of nitric oxide in schizophrenia: a review,” Schizophrenia Research, vol. 78, no. 1, pp. 69–86, 2005.
[2]
A. Dietrich-Muszalska and B. Olas, “Isoprostenes as indicators of oxidative stress in schizophrenia,” World Journal of Biological Psychiatry, vol. 10, no. 1, pp. 27–33, 2009.
[3]
A. Dietrich-Muszalska, B. Olas, and J. Rabe-Jablonska, “Oxidative stress in blood platelets from schizophrenic patients,” Platelets, vol. 16, no. 7, pp. 386–391, 2005.
[4]
H.-C. Li, Q.-Z. Chen, Y. Ma, and J.-F. Zhou, “Imbalanced free radicals and antioxidant defense systems in schizophrenia: a comparative study,” Journal of Zhejiang University Science B, vol. 7, no. 12, pp. 981–986, 2006.
[5]
R. D. Reddy and J. K. Yao, “Free radical pathology in schizophrenia: a review,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 55, no. 1-2, pp. 33–43, 1996.
[6]
N. Srivastava, M. K. Barthwal, P. K. Dalal et al., “Nitrite content and antioxidant enzyme levels in the blood of schizophrenia patients,” Psychopharmacology, vol. 158, no. 2, pp. 140–145, 2001.
[7]
J. K. Yao and M. S. Keshavan, “Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view,” Antioxidants and Redox Signaling, vol. 15, no. 7, pp. 2011–2035, 2011.
[8]
J. K. Yao, R. Reddy, L. G. Mcelhinny, and D. P. van Kammen, “Reduced status of plasma total antioxidant capacity in schizophrenia,” Schizophrenia Research, vol. 32, no. 1, pp. 1–8, 1998.
[9]
J. K. Yao, R. D. Reddy, L.G. Mcelhinny, and D. P. van Kammen, “Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications,” CNS Drugs, vol. 15, no. 4, pp. 287–310, 2001.
[10]
N. G. Gomes, M. G. Campos, J. M. Orf？o, and C. A. Ribeiro, “Plants with neurobiological activity as potential targets for drug discovery,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 33, no. 8, pp. 1372–1389, 2009.
[11]
D. F. Horrobin, “Schizophrenia as a membrane lipid disorder which is expressed throughout the body,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 55, no. 1-2, pp. 3–7, 1996.
[12]
D. P. van Kammen, J. K. Yao, and K. Goetz, “Polyunsaturated fatty acids, prostaglandins, and schizophrenia,” Annals of the New York Academy of Sciences, vol. 559, pp. 411–423, 1989.
[13]
D. F. Horrobin, M. S. Manku, H. Hillman, A. Iain, and M. Glen, “Fatty acid levels in the brains of schizophrenics and normal controls,” Biological Psychiatry, vol. 30, no. 8, pp. 795–805, 1991.
[14]
J. K. Yao, S. Leonard, and R. D. Reddy, “Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients,” Schizophrenia Research, vol. 42, no. 1, pp. 7–17, 2000.
[15]
M. Kunz, C. S. Gama, A. C. Andreazza et al., “Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 32, no. 7, pp. 1677–1681, 2008.
[16]
M. Kedzierska, B. Olas, B. Wachowicz et al., “An extract from berries of Aronia melanocarpa modulates the generation of superoxide anion radicals in blood platelets from breast cancer patients,” Planta Medica, vol. 75, no. 13, pp. 1405–1409, 2009.
[17]
V. Parikh, M. M. Khan, and S. P. Mahadik, “Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain,” Journal of Psychiatric Research, vol. 37, no. 1, pp. 43–51, 2003.
[18]
A. Pillai, V. Parikh, A. V. Terry Jr., and S. P. Mahadik, “Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain,” Journal of Psychiatric Research, vol. 41, no. 5, pp. 372–386, 2007.
[19]
M. Zhang, Z. Zhao, L. He, and C. Wan, “A meta-analysis of oxidative stress markers in schizophrenia,” Science China Life Sciences, vol. 53, no. 1, pp. 112–124, 2010.
[20]
A. O. Skinner, S. P. Mahadik, and D. L. Garver, “Thiobarbituric acid reactive substances in the cerebrospinal fluid in schizophrenia,” Schizophrenia Research, vol. 76, no. 1, pp. 83–87, 2005.
[21]
M. Peet, J. Laugharne, N. Rangarajan, and G. P. Reynolds, “Tardive dyskinesia, lipid peroxidation, and sustained amelioration with vitamin E treatment,” International Clinical Psychopharmacology, vol. 8, no. 3, pp. 151–153, 1993.
[22]
J. B. Lohr, R. Kuczenski, H. S. Bracha, M. Moir, and D. V. Jeste, “Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia,” Biological Psychiatry, vol. 28, no. 6, pp. 535–539, 1990.
[23]
H. S. Pall, A. C. Williams, D. R. Blake, and J. Lunec, “Evidence of enhanced lipid peroxidation in the cerebrospinal fluid of patients taking phenothiazines,” The Lancet, vol. 2, no. 8559, pp. 596–599, 1987.
[24]
G. Tsai, D. C. Goff, R. W. Chang, J. Flood, L. Baer, and J. T. Coyle, “Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia,” The American Journal of Psychiatry, vol. 155, no. 9, pp. 1207–1213, 1998.
[25]
G. Bjelakovic, D. Nikolova, L. L. Gluud, R. G. Simonetti, and C. Gluud, “Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases,” Cochrane Database of Systematic Reviews, vol. 3, Article ID CD007176, 2012.
[26]
G. Bjelakovic, D. Nikolova, and C. H. Gluud, “Meta-regression analyses, meta-analyses, and trial sequential analyses of the effects of supplementation with beta-carotene, vitamin A, and vitamin E singly or in different combinations on all-cause mortality: do we have evidence for lack of harm?” PLoS ONE, vol. 8, no. 9, Article ID e74558, 2013.
[27]
S. Eilat-Adar, T. Sinai, C. Yosefy, and Y. Henkin, “Nutritional recommendations for cardiovascular disease prevention review,” Nutrients, vol. 5, no. 9, pp. 3646–3683, 2013.
[28]
L. Hooper, P. A. Kroon, E. B. Rimm et al., “Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials,” The American Journal of Clinical Nutrition, vol. 88, no. 1, pp. 38–50, 2008.
[29]
R. Reddy, M. P. Sahebarao, S. Mukherjee, and J. N. Murthy, “Enzymes of the antioxidant defense system in chronic schizophrenic patients,” Biological Psychiatry, vol. 30, no. 4, pp. 409–412, 1991.
[30]
A. Dietrich-Muszalska and B. Kontek, “Lipid peroxidation in patients with schizophrenia,” Psychiatry and Clinical Neurosciences, vol. 64, no. 5, pp. 469–475, 2010.
[31]
C. S. Gama, M. Salvador, A. C. Andreazza, F. Kapczinski, and P. Silva Belmonte-de-Abreu, “Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: a study of patients treated with haloperidol or clozapine,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 30, no. 3, pp. 512–515, 2006.
[32]
I. Jeding, P. J. Evans, D. Akanmu et al., “Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs,” Biochemical Pharmacology, vol. 49, no. 3, pp. 359–365, 1995.
[33]
A. Dietrich-Muszalska, B. Kontek, and J. Rabe-Jab？ońska, “Quetiapine, olanzapine and haloperidol affect human plasma lipid peroxidation in vitro,” Neuropsychobiology, vol. 63, no. 4, pp. 197–201, 2011.
[34]
A. Dietrich-Muszalska, J. Kopka, and A. Kwiatkowska, “The effects of ziprasidone, clozapine and haloperidol on lipid peroxidation in human plasma (in vitro): comparison,” Neurochemical Research, vol. 38, no. 7, pp. 1490–1495, 2013.
[35]
A. Dietrich-Muszalska, “Evaluation of the effects of different concentrations of risperidone, corresponding to the drug doses used in treatment of schizophrenic patients, on lipid peroxidation in plasma and blood platelets at in vitro studies,” PsychIatria I PsychologIa Kliniczna, vol. 4, no. 4, pp. 215–223, 2004.
[36]
A. Dietrich-Muszalska and B. Olas, “Inhibitory effects of polyphenol compounds on lipid peroxidation caused by antipsychotics (haloperidol and amisulpride) in human plasma in vitro,” World Journal of Biological Psychiatry, vol. 11, no. 2, pp. 276–281, 2010.
[37]
Y. Sagara, “Induction of reactive oxygen species in neurons haloperidol,” Journal of Neurochemistry, vol. 71, no. 3, pp. 1002–1012, 1998.
[38]
S. Chung, H. Yao, S. Caito, J.-W. Hwang, G. Arunachalam, and I. Rahman, “Regulation of SIRT1 in cellular functions: role of polyphenols,” Archives of Biochemistry and Biophysics, vol. 501, no. 1, pp. 79–90, 2010.
[39]
B. Olas, M. Kedzierska, B. Wachowicz, A. Stochmal, and W. Oleszek, “Effects of polyphenol-rich extract from berries of Aronia melanocarpa on the markers of oxidative stress and blood platelet activation,” Platelets, vol. 21, no. 4, pp. 274–281, 2010.
[40]
A. F. Schatzberg and C. B. Nemeroff, Eds., The American Psychiatric Publishing Textbook of Psychopharmacology, American Psychiatric Publishing, Arlington, Va, USA, 2004.
[41]
E. Stip, S. Zhornitsky, H. Moteshafi et al., “Ziprasidone for psychotic disorders: a meta-analysis and systematic review of the relationship between pharmacokinetics, pharmacodynamics, and clinical profile,” Clinical Therapeutics, vol. 33, no. 12, pp. 1853–1867, 2011.
[42]
D. V. Sheehan, Y. Lecrubier, K. H. Sheehan et al., “The mini-international neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10,” Journal of Clinical Psychiatry, vol. 59, supplement 20, pp. 22–33, 1998.
[43]
C. A. Rice-Evans, A. T. Diplock, and M. C. Symons, Techniques in Free Radical Research, Elsevier, New York, NY, USA, 1991.
[44]
B. Wachowicz and J. Kustron, “Effect of cisplatin on lipid peroxidation in pig blood platelets,” Cytobios, vol. 70, pp. 41–47, 1992.
[45]
S. P. Machadik, S. Mukherjee, R. Scheffer, E. E. Correnti, and J. S. Mahadik, “Elevated plasma lipid peroxides at the onset of nonaffective psychosis,” Biological Psychiatry, vol. 43, no. 9, pp. 674–679, 1998.
[46]
R. G. McCreadie, E. MacDonald, D. Wiles, G. Campbell, and J. R. Paterson, “The nithsdale schizophrenia surveys. XIV: plasma lipid peroxide and serum vitamin E levels in patients with and without tardive dyskinesia, and in normal subjects,” The British Journal of Psychiatry, vol. 167, no. 5, pp. 610–617, 1995.
[47]
A. Dietrich-Muszalska and B. Olas, “Modifications of blood platelet proteins of patients with schizophrenia,” Platelets, vol. 20, no. 2, pp. 90–96, 2009.
[48]
A. Dietrich-Muszalska, B. Olas, R. G？owacki, and E. Bald, “Oxidative/nitrative modifications of plasma proteins and thiols from patients with schizophrenia,” Neuropsychobiology, vol. 59, no. 1, pp. 1–7, 2009.
[49]
D. Taylor, C. Paton, and R. Kerwin, The South London and Maudsley NHS Trust. Prescribing Guidelines, Martin Dunitz, Taylor & Francis, London, UK, 7th edition, 2003.
[50]
P. S. Naidu and S. K. Kulkarni, “Quercefin, a bioflavonoid, reverses haloperidol-induced catalepsy,” Methods and Findings in Experimental and Clinical Pharmacology, vol. 26, no. 5, pp. 323–326, 2004.
[51]
B. Olas and B. Wachowicz, “Resveratrol, a phenolic antioxidant with effects on blood platelet functions,” Platelets, vol. 16, no. 5, pp. 251–260, 2005.
[52]
M. Bijak, M. Bobrowski, M. Borowiecka, A. Pods？dek, J. Golański, and P. Nowak, “Anticoagulant effect of polyphenols-rich extracts from black chokeberry and grape seeds,” Fitoterapia, vol. 82, no. 6, pp. 811–817, 2011.
[53]
M. Naruszewicz and M. Dluzniewski, “Flavonoids from choheberry fruits (Aronia melanocarpa) reduce oxidative stress and inflammation in patients with coronary artery disease treated with statins (Short lectures),” Planta Medica, vol. 73, 2007.
[54]
X. F. Li, Y. L. Zheng, M. H. Xiu, D. C. Chen, T. R. Kosten, and X. Y. Zhang, “Reduced plasma total antioxidant status in first-episode drug-naive patients with schizophrenia,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 35, no. 4, pp. 1064–1067, 2011.
[55]
J. K. Yao, R. Reddy, and D. P. van Kammen, “Abnormal age-related changes of plasma antioxidant proteins in schizophrenia,” Psychiatry Research, vol. 97, no. 2-3, pp. 137–151, 2000.
[56]
M. Raffa, F. Atig, A. Mhalla, A. Kerkeni, and A. Mechri, “Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients,” BMC Psychiatry, vol. 11, article 124, 2011.
[57]
S. Grignon and J. M. Chianetta, “Assessment of malondialdehyde levels in schizophrenia: a meta-analysis and some methodological considerations,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 31, no. 2, pp. 365–369, 2007.
[58]
B. M. Al-Chalabi, I. A. J. Thanoon, and F. A. Ahmed, “Potential effect of olanzapine on total antioxidant status and lipid peroxidation in schizophrenic patients,” Neuropsychobiology, vol. 59, no. 1, pp. 8–11, 2009.
[59]
G. Dadheech, S. Mishra, S. Gautam, and P. Sharma, “Evaluation of antioxidant deficit in schizophrenia,” Indian Journal of Psychiatry, vol. 50, no. 1, pp. 16–20, 2008.
[60]
M. Padurariu, A. Ciobica, I. Dobrin, and C. Stefanescu, “Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics,” Neuroscience Letters, vol. 479, no. 3, pp. 317–320, 2010.
[61]
S. Kropp, V. Kern, K. Lange et al., “Oxidative stress during treatment with first- and second-generation antipsychotics,” Journal of Neuropsychiatry and Clinical Neurosciences, vol. 17, no. 2, pp. 227–231, 2005.
